Modalités de l’utilisation de l’alpha-glucosidase recombinante humaine (Myosine TM) et du suivi des patients adultes

Annane D, Caillaud C, Laforêt P, Maire I, Nicolino M, Orlikovski D.
 Recommandations du Comité d’Evaluation du traitement de la maladie de Pompe 2008.
 In adult Pompe disease, it is recommended to assess patients by MFM initially and every 6 months or annually by the reference center for the patient in the monitoring of the Myosine protocol. (in French).

Keywords : Pompe disease, Myosyme, recommendations, protocol, clinical trials

 

Articles dans les revues scientifiques

Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)

Stam M, Wadman RI, Wijngaarde CA, Bartels B, Asselman FL, Otto LAM, Goedee HS, Habets LE, de Groot JF, Schoenmakers MAGC, Cuppen I, van den Berg LH, van der Pol WL. BMJ Open. 2018. 30;8(7):e019932.  Protocol of the "SPACE" in wich MFM is used as an outcome measure....

read more